Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

The CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

Rare Guillain-Barré Syndrome cases were found after ChAdOx1 vaccine in India; vigilance is urged despite vaccine’s overall safety.

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

We present a case of Guillain-Barré syndrome in a child who received hepatitis A vaccine 5 days before onset of the clinical symptoms. In our patient, the association of Guillain-Barré syndrome ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

Guillain-Barré Syndrome & Other Serious Neurological Adverse Events Following Vaccination Until now, medical science cannot completely explain the cause of or mechanisms behind the development of ...